嗜铬粒蛋白A
烯醇化酶
神经内分泌肿瘤
预测值
医学
生物标志物
诊断生物标志物
内科学
肿瘤科
诊断准确性
病理
生物
免疫组织化学
生物化学
作者
Marina Tsoli,Anna Koumarianou,Anna Angelousi,Gregory Kaltsas
标识
DOI:10.1016/j.beem.2023.101785
摘要
The management of neuroendocrine tumors (NETs) represents a clinical challenge due to heterogeneity of their clinical behaviour, molecular biology and response to treatment. Over the years, several circulating biomarkers have been developed for the early diagnosis and follow-up of NETs. The specific secretory products of tumors associated with a secretory syndrome (functioning tumors) may be used as diagnostic and/or prognostic biomarkers while the most common non-specific circulating biomarkers, that may be increased in both functioning and non-functioning tumors, are chromogranin A and the neuron specific enolase. However, the diagnostic accuracy as well as the prognostic and predictive value of these biomarkers are limited and novel techniques of multianalyte analysis of regulators of tumor biology have been developed. The NETest has been most extensively studied and proved to be useful in NET diagnosis, early detection of post-operative recurrence and prediction of response to treatment but further investigation establishing higher level of evidence is required for implementation in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI